Cargando…
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Emergence of the Solution to an Important Unmet Need
Alzheimer’s Disease (AD) represents an increasing problem as the overall population ages. The identification of reliable biomarkers of AD has, therefore, become increasingly important. This is not only for risk prediction and diagnosis in order to provide appropriate care, but also to identify those...
Autores principales: | Teunissen, CE, Willemse, EAJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Communications and Publications Division (CPD) of the IFCC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975183/ https://www.ncbi.nlm.nih.gov/pubmed/27683444 |
Ejemplares similares
-
Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015) -
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions
por: Langdahl, Bente Lomholt, et al.
Publicado: (2018) -
Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
por: Huynh, Rose Ann, et al.
Publicado: (2017) -
Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017) -
Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
por: Das, Shreyasee, et al.
Publicado: (2023)